University of Florida Builds Pharmacokinetic Model to Predict Kratom Drug Interactions in Humans

Why it matters

Millions of Americans use kratom alongside prescription medications, yet until now there has been no validated model to predict how mitragynine interacts with commonly prescribed drugs. This PBPK model could directly inform clinical guidance and drug interaction warnings.

The big picture

Kratom's primary alkaloid, mitragynine, is metabolized mainly by CYP3A4, the enzyme responsible for processing roughly half of all prescription drugs. Prior work showed even a low 2g dose of kratom tea can increase midazolam blood levels by 40–50%. This new physiologically based pharmacokinetic (PBPK) model from University of Florida researchers builds on that foundation to quantitatively predict interaction severity across multiple drug combinations.

Key findings

• Researchers developed a PBPK model specifically for mitragynine to predict drug-drug interactions at clinically relevant doses
• The model addresses how mitragynine inhibits CYP3A4 and CYP2D6 enzymes, which metabolize hundreds of common medications
• Prior clinical data showed kratom tea raised midazolam plasma concentrations 1.4–1.5-fold, validating the model's relevance
• The model is designed to support clinical translation of mitragynine as a potential opioid use disorder treatment
• Results are published in ACS Pharmacology & Translational Science (2026, Vol. 9, Issue 3)

What they say

The University of Florida research team, led by Yi-Hua Chiang and Siva Rama Raju Kanumuri, developed the model to support "clinical translation and prediction of drug interaction" for mitragynine as it moves toward potential therapeutic evaluation.

Bottom line

**A new pharmacokinetic model from University of Florida researchers can now predict how kratom's main alkaloid interacts with prescription drugs — a critical step toward safe clinical use and consumer safety warnings.**